Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 74

Results For "Inc"

6647 News Found

Relmada gains FDA backing for two registrational trials and reports 92% response with NDV-01 in bladder Cancer
Clinical Trials | November 10, 2025

Relmada gains FDA backing for two registrational trials and reports 92% response with NDV-01 in bladder Cancer

Relmada expects to initiate its Phase 3 program in the first half of 2026


Biohaven disappointed as rare disease therapy faces FDA setback 'despite promising results'
Drug Approval | November 10, 2025

Biohaven disappointed as rare disease therapy faces FDA setback 'despite promising results'

The FDA setback highlights ongoing tensions between patient needs, regulatory processes, and the use of real-world evidence in evaluating treatments for rare diseases


Novo Nordisk India partners with Emcure to commercialise Poviztra in India
News | November 10, 2025

Novo Nordisk India partners with Emcure to commercialise Poviztra in India

Poviztra is a second brand of Wegovy


Poly Medicure posts Q2 FY26 consolidated net profit at Rs. 91.83 Cr
News | November 09, 2025

Poly Medicure posts Q2 FY26 consolidated net profit at Rs. 91.83 Cr

Poly Medicure has reported total income of Rs. 477.82 crore during the period ended September 30, 2025


Syngene International reports Q2 FY26 consolidated PAT at Rs. 67.1 Cr
News | November 09, 2025

Syngene International reports Q2 FY26 consolidated PAT at Rs. 67.1 Cr

Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025


Piramal Pharma posts Q2 FY26 consolidated loss at Rs. 99.22 Cr
News | November 09, 2025

Piramal Pharma posts Q2 FY26 consolidated loss at Rs. 99.22 Cr

Piramal Pharma has reported total income of Rs. 2,109.32 crore during the period ended September 30, 2025


Solara Active Pharma Sciences posts Q2 FY26 consolidated loss at Rs. 10.10 Cr
News | November 09, 2025

Solara Active Pharma Sciences posts Q2 FY26 consolidated loss at Rs. 10.10 Cr

Solara Active Pharma Sciences has reported total income of Rs. 314.03 crore during the period ended September 30, 2025


Caplin Point Laboratories reports Q2 FY26 consolidated PAT at Rs. 154.45 Cr
News | November 09, 2025

Caplin Point Laboratories reports Q2 FY26 consolidated PAT at Rs. 154.45 Cr

Caplin Point Laboratories has reported total income of Rs. 564.41 crore during the period ended September 30, 2025


SMS Pharmaceuticals post Q2 FY26 consolidated PAT at Rs. 25.31 Cr
News | November 09, 2025

SMS Pharmaceuticals post Q2 FY26 consolidated PAT at Rs. 25.31 Cr

SMS Pharmaceuticals has reported total income of Rs. 243.86 crore during the period ended September 30, 2025


Sun Pharmaceutical Industries posts consolidated Q2 FY26 PAT higher at Rs. 3,137.09 Cr
News | November 08, 2025

Sun Pharmaceutical Industries posts consolidated Q2 FY26 PAT higher at Rs. 3,137.09 Cr

Sun Pharmaceutical Industries has reported total income of Rs. 14,948.23 crore during the period ended September 30, 2025